Aktieanalys

Cantargia Q2 2023: CAN10 Approaching the Clinic - Redeye

{newsItem.title}

Redeye Publicerad: 23 Aug 2023 07:26

Redeye comments on Cantargia’s second quarter report 2023. An application to start a clinical trial with the second project, CAN10, was submitted and approved since our last update.

Länk till analysen i sin helhet: https://www.redeye.se/research/936271/cantargia-q2-2023-can10-approaching-the-clinic?utm_source=finwire&utm_medium=RSS

Nyheter om Cantargia

Läses av andra just nu

Om aktien Cantargia

Senaste nytt